Ya-Fei Zhu's research while affiliated with First Affiliated Hospital of China Medical University and other places

Publications (4)

Article
Full-text available
To investigate effect and possible mechanisms of silencing human WFDC2 (HE4) gene on biological behavior changes as cell proliferation, apoptosis, movement and invasion of human serous ovarian cancer cell line SKOV3. Lentiviral WFDC2 gene sequence of small interfering siRNA was stablely transfected into SKOV3 identified by Q-PCR and western-blot. O...
Article
Full-text available
To investigate the value of serum human epididymis protein 4 (HE4) in differential diagnosis of patients with low-grade serous (LGSC) and high-grade serous carcinoma (HGSC) serous ovarian cancer. LGSC and HGSC serous ovarian cancer were diagnosed by the two-tier grade system, serum levels of HE4 and carbohydrate antigen 125 (CA125) were measured by...
Article
Inside out transobturator vaginal tape (TVT-O) and tension-free vaginal tape (TVT) are predominant surgical treatments for female stress urinary incontinence. This meta-analysis evaluated the complications and cure rates of TVT-O versus TVT. A comprehensive literature search was conducted according to the Cochrane Collaboration methodology to ident...

Citations

... 8 Therefore, a definite correlation of HE4 with the pathogenesis of epithelial ovarian cancer is expected. According to recent studies, HE4 mainly influences the ability of ovarian cancer cells to invade and metastasize, 9,10 which is a significant factor responsible for poor prognosis and overall survival. HE4 was first shown to be highly expressed in ovarian cancer and was identified as a serum marker by Hellstrom et al. 6 Moore et al. analyzed serum and urine samples obtained before surgery from women with an adnexal mass for CA-125, HE4, inhibin, EGFR, SMRP, CA72-4, activin, osteopontin, and ERBB2 (Her2). ...
... There is an interact between HE4 and steroid hormones: Treatment of ovarian cancer cells with steroid hormones promoted nuclear translocation of HE4 and cells became less responsive to hormonal therapy, which was restored by blocking HE4 from entering the nucleus [11]. Its presence at the cellular level was also demonstrated in malignant ovarian tumors and in a wide range of benign and borderline ovarian lesions [12,13]. It is also found in endometrial carcinoma patients but to our knowledge, its presence in the USC tissue was examined in only one study and the expression rate was found 38.1% [14]. ...
... In contrast, Novara et al. found similar subjective cure rates between slings but higher objective cure rates for the RP group, albeit with a short follow-up [25]. Other randomized short- [26] and long-term [27] follow-up studies found no differences in subjective and objective cure rates, which is consistent with several other meta-analyses [28][29][30]. As mentioned above, the TOMUS study had a follow-up of 12 months and showed a higher subjective cure rate for the RP group [23]. ...